Kyle Fitzgerald

Kyle Fitzgerald is a seasoned scientist currently serving as a Senior Scientist at Mythic Therapeutics, Inc. since September 2018, where Kyle leads characterization and developability assessments for Antibody Drug Conjugates aimed at improving outcomes for cancer patients. Previous experience includes a Scientist role at Elstar Therapeutics Inc., focusing on multifunctional proteins, and an Associate Scientist position at 121Bio LLC, where Kyle contributed to antibody discovery technologies. Earlier positions include a Sr. Research Associate at Momenta Pharmaceuticals, a Research Associate II at Illumina, and a Research Assistant at Affomix Corporation. Kyle holds a BS in Biological Sciences from the University of Vermont and an MS in Molecular and Cell Biology from Quinnipiac University, with ongoing studies in the CORe Curriculum at Harvard Business School Online.